15912results about "Extracellular fluid disorder" patented technology

The invention provides a preparation method of a novel recombinant humanized collagen hydrogel. The method comprises the following steps: recombinant humanized collagen and a dialdehyde crosslinking agent are subjected to a reaction, the concentration of the dialdehyde crosslinking agent is 0.01-0.25%, and the recombinant humanized collagen is one or more of recombinant humanized type II collagen, recombinant humanized type III collagen and recombinant humanized type XVII collagen, and the recombinant humanized collagen has a triple helix structure. The aldehydes cross-linking agent suitable for the recombinant humanized collagen, especially the recombinant humanized collagen with a triple helix structure, and the optimal reaction conditions are determined.

To provide constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5Kb.SOLUTION: The present invention implements cellular large protein reconstitution by providing to a target cell two or more fragments of large protein fused to split inteins to promote intein-mediated trans-splicing and reconstitute the functional protein.SELECTED DRAWING: None

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

Disclosed in the present invention are a polycyclic derivative, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in the preparation of a drug for treating diseases. The compound has a structure as represented by formula (I).

Provided are diaminocyclopentyl substituted heteroaryl derivatives, the use thereof and a preparation method therefor. In particular, the present disclosure relates to compounds represented by formula (I)each substituent of which is defined in the description, and a preparation method therefor. The compounds can be used as PCSK9 inhibitors to prevent and / or treat PCSK9-mediated diseases and disorders.

The invention provides a plant lactobacillus capable of promoting mineral absorption and transport and application of the plant lactobacillus. The invention provides a plant lactobacillus of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.32404. The invention also provides a culture, a sterilized solution, a supernatant, a filtrate, a diluent, a precipitate or freeze-dried powder, a composition and a probiotic preparation containing the plant lactobacillus, and related applications and methods thereof.

The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.

The invention provides a compound as shown in a formula I, or pharmaceutically acceptable salt, stereoisomer or tautomer thereof. The compounds have been demonstrated to be good GLP-1 receptor agonists. In addition, the compound is simple in preparation method and has a certain application prospect. # imgabs0 #

The invention provides an artificial nucleic acid molecule which is used for improving the expression quantity of target amino acid, polypeptide or protein. The artificial nucleic acid molecule at least comprises a target 5'untranslated region (UTR), a target coding region (CDS) and a target 3 'untranslated region (UTR). Wherein the sequence of the target 5 'UTR is one of the following sequences: 5' UTR of a high-expression gene and a 5 'UTR variant of the high-expression gene. The sequence of the target 3 'UTR is one of the following sequences: 3' UTR of a high-expression gene and a 3 'UTR variant of the high-expression gene. Optionally, the artificial nucleic acid molecule may further comprise, for example, a 5 '-end cap structure (Cap), a PolyA tail. The 5 'UTR and the 3' UTR have regulating effects on translation and stability of nucleic acid molecules, so that the 5 'UTR, the 3' UTR and variants thereof are selected from high-expression genes, the nucleic acid molecules can be further stabilized and are not easy to degrade, and the amount of protein or polypeptide obtained by translation of the nucleic acid molecules can be increased. The invention also provides methods for making, delivering, and using such artificial nucleic acid molecules, as well as the use of the artificial nucleic acid molecules for the treatment and / or prevention of related diseases or disorders.

Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and / or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and / or thrombopoietin receptor (TPO-R) agonists.

A synergistic composition for improving the bioaccessibility of minerals comprises lutein, a casein phosphopeptide, or a 1, 3-dioleoyl-2-palmitic acid triglyceride, preferably in combination with one or more non-digestible oligosaccharides. These compositions are useful for the prevention and / or treatment of mineral deficiency and related conditions, preferably anemia, said minerals comprising iron and / or calcium.

The present application relates to an RNA inhibitor or a pharmaceutically acceptable salt thereof for inhibiting the expression of an LPA gene comprising a complementary region of an antisense strand, the complementary region comprises at least 15 consecutive nucleotides, wherein the antisense strand comprises the following nucleotide sequence: any sequence of SEQ ID NO. 414-418, a sequence having at least 15 consecutive nucleotides identical to that in SEQ ID NO. 414-418, or a sequence having no more than three different nucleotides from the above sequences. The RNA inhibitor of the present application directly degrades LPA mRNA, continuously and efficiently inhibits LPA gene expression, and can be used to treat or prevent cardio-cerebrovascular diseases mediated by LPA genes.

The invention provides an anti-human CD117 monoclonal antibody and an application thereof. The anti-human CD117 monoclonal antibody comprises three heavy chain complementary determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementary determining regions CDR-L1, CDR-L2 and CDR-L3, the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and the amino acid sequence of the light chain complementary determining regions is as shown in SEQ ID NO: 6. The amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. Compared with the existing known anti-human CD117 monoclonal antibody, the antibody disclosed by the invention shows better cellular level biology, and is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The invention provides conotoxin-derived anticoagulant polypeptide Cb-13 and application thereof, and belongs to the technical field of biological medicine. The invention provides an anticoagulant polypeptide Cb-13. The amino acid sequence of the anticoagulant polypeptide Cb-13 comprises SEQ ID No.1. The invention also provides a coding gene of the anticoagulant polypeptide Cb-13, and provides that the anticoagulant polypeptide Cb-13 does not have hemolytic activity and does not have cytotoxicity when the concentration is 400 [mu] M or below. The anticoagulant polypeptide Cb-13 disclosed by the invention has a prolonging effect on plasma recalcification and coagulation time, has an anticoagulant effect, has small influence on bleeding, and also has an obvious promoting effect on plasmin and uPa. Meanwhile, it is also proved that the anticoagulant polypeptide Cb-13 can inhibit thrombus formation, that is, the anticoagulant polypeptide Cb-13 has in-vivo and in-vitro fibrinolytic effect and anticoagulant effect, has small bleeding risk, and can be used as an antithrombotic or thrombolytic drug.

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

The invention relates to the technical field of gene engineering, in particular to tyrosine sulfated recombinant hirudin as well as a preparation method and application thereof. In order to improve the safety and synthesis yield of the recombinant hirudin and reduce the production cost, the tyrosine sulfated recombinant hirudin is successfully prepared through an algae expression vector.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The invention provides cat serum albumin and application thereof, and relates to the technical field of protein engineering. According to the invention, mutation is carried out on the cat serum albumin for the first time to obtain a beneficial mutation site, so that the cat serum albumin mutant which can be highly expressed in a pichia pastoris system is obtained. In addition, the cat serum albumin mutant I31L also has the effect of treating ascites due to cirrhosis, and the treatment effect is obviously higher than that in the prior art. A new biological material is provided for application of the cat serum albumin, and a foundation is laid for genetic engineering modification of the cat serum albumin.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

The invention relates to the technical field of biological medicines, in particular to a sulfonamide compound for treatment and an enantiomer thereof as well as a preparation method and application thereof, and has the beneficial effects that the provided sulfonamide compound and the enantiomer thereof have the characteristics of strong stability, longer action effect, better drug effect and the like; the compound is a better diuretic and new anti-encephaledema medicine.

The invention discloses a hydrogel compound, a preparation method and application, and belongs to the technical field of hydrogel. The hydrogel compound provided by the invention is prepared from the following raw materials: a hydrogel matrix, sodium glycerophosphate pentahydrate and a functional drug, the hydrogel matrix is prepared from chitosan, hydroxybutyl chitosan and methacrylated gelatin; the functional medicines comprise cannabidiol, tobramycin and acetylsalicylic acid; the hydrogel compound provided by the invention has excellent mechanical properties and water vapor permeability, also has excellent slow release property and wound healing ability, and can be widely applied to preparation of medicines for treating wounds. In addition, the preparation method of the hydrogel compound provided by the invention is simple to operate and beneficial to practical application.

The invention discloses a destabilizing enzyme fusion protein with improved activity, and the amino acid sequence of the destabilizing enzyme fusion protein is as shown in SEQ ID No.3 or SEQ ID No.5. According to the destabilizing enzyme fusion protein disclosed by the invention, the bacteriostatic activity, thrombolytic activity and isopeptidase activity of the destabilizing enzyme fusion protein are improved by optimizing the expression strategy and modifying the sequence of destabilizing enzyme Wpdestalase from whitmania pigra; and the application prospect and the application space of the Wpestabase are improved.

The invention discloses an oral care desensitization paste and a preparation method thereof, and mainly relates to the technical field of dental medicines. The oral care desensitization cream is prepared from the following components: bioactive glass, strontium chloride, sodium chloride, silicon dioxide, sodium carboxymethyl cellulose, polyethylene glycol 400, a xanthan gum solution, sodium lauryl sulfate, sodium lauroyl sarcosinate, titanium dioxide, beta-glucan, saccharin sodium salt, sorbitol, methylparaben, propyl hydroxybenzoate, edible essence and water. Compared with the prior art, the oral care desensitization paste disclosed by the invention can be used for sealing dentinal tubules and treating hemodia; the traditional Chinese medicine composition can also be used for treating plaque gingivitis, relieving and reducing gingival bleeding and inhibiting and reducing dental plaque; and meanwhile, the condition of mistakenly swallowing and eating in the using process is reduced.